Company Overview and News

Longfor to ramp up emphasis on residential and commercial property leasing

2017-12-18 scmp
Longfor Properties Co, one of the mainland’s top 10 developers, is seeking to expand its footprint in commercial and residential property leasing in an effort to tap new growth engines as the domestic property market cools.

Jones Day welcomes M&A partner Charles Chau in Hong Kong

2017-08-16 marketwired
HONG KONG, CHINA--(Marketwired - Aug 16, 2017) - The global law firm Jones Day has announced that Charles Chau has joined the Firm's Hong Kong Office as a partner in its M&A Practice.

ICD and Wingate sell Fitness First gym for $17.55m

ICD Property, the Chinese-backed developer of one of Melbourne's largest high-rise residential towers, and investment firm Wingate have cashed out of a Fitness First investment in Cheltenham for $17.55 million.

ICD and Wingate sell Fitness First gym for $17.55m

ICD Property, the Chinese-backed developer of one of Melbourne's largest high-rise residential towers, and investment firm Wingate have cashed out of a Fitness First investment in Cheltenham for $17.55 million.

China's Most Profitable Industry Becomes One of the Toughest

2016-10-06 seekingalpha
Chinese real estate is no longer the easiest legal risk-adjusted money-making business in the world. It’s been a swift reversal. The impact will be felt across the board, by larger publicly-traded real estate developers like Xinyuan Real Estate Co., Ltd. (NYSE:XIN) , SOHO China Limited (OTCPK:SOHOF), Sino-Ocean Land Holdings Limited (OTCPK:SIOLF) and Central China Real Estate Limited (0832.HK) as well as REITs with exposure to China’s property market.

Real Estate Prices in China: For Many, Higher Means Happier

2016-10-06 seekingalpha
China’s government is engaged in mortal combat to control rapidly-rising real estate prices ... or so you would believe from reading the newspapers and listening to all the economic commentary. But it’s not entirely true. The reality is, China’s government is trying to navigate a tricky path between the interests of current homeowners and those who’ve yet to join the housing ladder.

Hong Kong stocks deepen losses, Chinese developers hit hardest

2016-06-10 scmp
Gold shares rally after reports said George Soros is back to the market with bearish investments, favouring gold and gold-mining shares

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

7h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

8h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

18h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...